---
title: "Tempest Therapeutics kündigt Privatplatzierung und unregistrierten Aktienverkauf an"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/275172834.md"
datetime: "2026-02-06T21:13:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275172834.md)
  - [en](https://longbridge.com/en/news/275172834.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275172834.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275172834.md) | [繁體中文](https://longbridge.com/zh-HK/news/275172834.md)


# Tempest Therapeutics kündigt Privatplatzierung und unregistrierten Aktienverkauf an

Tempest Therapeutics Inc. hat eine Privatplatzierung und einen unregistrierten Aktienverkauf bekannt gegeben. Im Rahmen einer Transaktion am 3. Februar 2026 wurden rund 8,3 Millionen neue Stammaktien an Erigen ausgegeben. Nach Abschluss dieser Ausgabe hält Erigen etwa 61 % der ausstehenden Stammaktien von Tempest Therapeutics, während die bisherigen Aktionäre rund 39 % besitzen. Die Aktien wurden gemäß einer Ausnahmeregelung des US-Wertpapiergesetzes im Rahmen eines privaten Angebots ausgegeben und sind nicht registriert. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempest Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-041190), on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Tempest Therapeutics, Inc. (TPST.US)](https://longbridge.com/en/quote/TPST.US.md)
- [UroGen Pharma Ltd. (URGN.US)](https://longbridge.com/en/quote/URGN.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)

## Related News & Research

- [Prelude Therapeutics reports $99.5 mln net loss for 2025](https://longbridge.com/en/news/278542482.md)
- [Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study | INTS Stock News](https://longbridge.com/en/news/278874097.md)
- [Abbott Laboratories publishes 2025 annual report](https://longbridge.com/en/news/279092153.md)
- [Acurx Pharmaceuticals Q4 net loss narrows on lower R&D spend](https://longbridge.com/en/news/279032442.md)
- [Corvus’ Soquelitinib Trial Completion Adds a New Catalyst in the Atopic Dermatitis Market](https://longbridge.com/en/news/278917368.md)